Pharma's Market
SPECIAL REPORT
MOST SHARED
- China January Trade Surplus Soars as Imports Crumble
- Jobs You Can Do Forever
- Lightning Round: Yahoo!, CEC Entertainment, Standard Pacific and More
- China City Raises Cash Subsidies for Home Buyers
- Euro Near Two Month Highs After Greece; Outlook Uncertain
- Gold in Tight Range After Greece Deal, CME cut
- Tesla Unveils First SUV: Model X
- US Crude Dips After Three Days of Gains
- Steelers' Antonio Brown Spends Super Bowl Week with Twitter Fan Turned BFF
- Cramer: Berkshire Hathaway Is a 'Screaming Buy'
- New York Fashion Week Hits the Runway as Colors Pop
- Mulling Buffett's Stock Advice? Get in With REITs: Fund Managers
- LinkedIn Earnings Bode Well for Hiring and Social Media
- Top Five Mistakes to Avoid in Online Dating
- Victor Cruz ‘Understands’ Gisele's Super Bowl Frustrations
- Tamminen: The United States of India
- Unusual Volume: Taleo Jumps After Oracle's $1.9 Billion Offer
- Warren Buffett: Stocks Will Outperform Gold and Bonds .. and They're Safer 'By Far'
- So Now You Can’t Give Microsoft Away?
- The Secret Lives of Traders—Seeking the Next Hot Thing
- China January Trade Surplus Soars as Imports Crumble
- Markets Finally Get Greek Deal —So Where's the Rally?
- Warren Buffett: Stocks Will Outperform Gold and Bonds
- Alibaba Plans to Buy Back Yahoo Stake, Go Private
- Greece Deal Fails to Convince, EU Demands More
- 'Mortgage Deal from Hell' Hurts Sound Borrowers: Bove
- Clint Eastwood: Super Bowl Ad Endorses No One
- Zynga, Hasbro Partner to Make Toys, Games
RSS FEED
Wyeth and Elan Face Big Test
Text Size 
Reporter
 |
AP Wyeth |
We just finished back-to-back coverage of the world's largest oncology and diabetes conferences. Now we get a bit of a break before shifting our attention to Alzheimer's.
Specifically, analysts say Wyeth [WYE
Loading...
()
]and Elan[ELN
Loading...
()
] could be out with basic results on a mid-stage test for their drug by the end of this month.
Then they're expected to present the detailed data at the International Conference on Alzheimer's Disease in late July. Some analysts think if the drug shows promise it could become the biggest selling drug in history.
Bill Tanner at Leerink Swann writes in a research note to clients today that "investors should not expect to see significant treatment effects given the relatively small size of the trial and the heterogeneity of the patients population." (Dear Elanians: I'm just reporting what the man said, please do not flood my inbox with complaints about what you might see as his bearish analysis.)
Nonetheless, he believes there will probably be enough positive data for the companies to continue to move forward. Coincidentally, Brian McCarthy, a biotech analyst at Merriman Curhan Ford initiated coverage today of ELN with a Buy rating.
But he agrees with Tanner about the pending test results. "We believe a statistically significant response in Phase 2 (mid-stage clinical trial) is unlikely given the small number of patients," McCarthy writes.
He justifies his Buy rating by saying, "Positive Phase 2 Alzheimer's data could add approximately $7 in the near-term, or approximately $15 longer term if (the drug) succeeds for AD."
But buyer beware. Both analysts also say that ELN shares could be volatile in the coming weeks.
Leerink Swann may trade ELN shares. Typically, if a company doesn't have any disclosures on a stock I won't mention it. I only point them out if they exist. But since MCF is initiating coverage today I will say it has none to make.
An estimates five million Americans have Alzheimer's. That number is expected to multiply.
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes
